Daily Endocrinology Research Analysis
Analyzed 109 papers and selected 3 impactful papers.
Summary
A mechanistic study in thyroid oncology reveals loss of heterozygosity can unmask recessive germline mutations in mitochondrial complex I, driving Warburg metabolism in oncocytic carcinoma. A large prospective real-world cohort shows telemedicine-enhanced integrated care for gestational diabetes improves maternal glycemia and multiple perinatal outcomes with a dose–response to engagement. A population-based cohort links the co-occurrence of gestational diabetes and hypertensive disorders of pregnancy to markedly higher all-cause and premature mortality, underscoring postpartum cardiometabolic risk.
Research Themes
- Mitochondrial metabolism and germline–somatic interactions in thyroid cancer
- Telemedicine-enabled integrated care for gestational diabetes
- Postpartum cardiometabolic risk after gestational complications
Selected Articles
1. Loss of heterozygosity exposes germline mutations in complex I and drives Warburg metabolism in oncocytic carcinoma of the thyroid.
The authors establish an oncocytic thyroid carcinoma cell line (UT946) with profound complex I dysfunction and demonstrate that a nuclear-encoded NDUFS1 loss-of-function mutation, inherited as a recessive germline allele, becomes pathogenic via tumor LOH. Reanalysis of 91 tumors shows LOH-driven exposure of recessive germline mutations in complex I subunits as a recurrent mechanism, reinforcing selective pressure for complex I impairment and metabolic reprogramming.
Impact: This study uncovers a previously unrecognized germline-to-somatic mechanism for complex I inactivation in cancer, advancing our understanding of thyroid oncocytic carcinoma metabolism. It offers mechanistic targets and genetic counseling implications.
Clinical Implications: Findings suggest considering germline testing of complex I genes in oncocytic thyroid carcinoma and exploring metabolic vulnerabilities (complex I dependency) for therapeutic strategies.
Key Findings
- Established and characterized a new OCT cell line (UT946) with severe ETC complex I dysfunction and a Warburg phenotype.
- Cytoplasmic hybrid studies traced the complex I defect to a nuclear-encoded NDUFS1 loss-of-function mutation inherited as a recessive germline allele.
- Tumor LOH exposed the recessive germline mutation, causing functional complex I loss.
- Reanalysis of 91 OCT genomes showed LOH-driven exposure of recessive complex I subunit mutations as a recurrent mechanism.
Methodological Strengths
- Rigorous mechanistic approach including novel cell line generation and cytoplasmic hybrid assays
- Genome-wide reanalysis across 91 tumors to establish recurrence of the mechanism
Limitations
- Preclinical nature limits direct clinical translation; in vivo validation not reported
- Findings are focused on oncocytic thyroid carcinoma and may not generalize to other cancers
Future Directions: Assess germline prevalence of complex I variants in OCT cohorts, evaluate therapeutic strategies exploiting complex I loss, and validate in vivo metabolic dependencies.
Oncocytic (Hürthle cell) carcinoma of the thyroid (OCT) is characterized by widespread loss of heterozygosity (LOH), mitochondrial accumulation, and recurrent mitochondrial DNA mutations leading to impairment of complex I. Here, we establish and characterize a novel OCT cell line, UT946, which displays severe mitochondrial electron transport chain dysfunction and a Warburg metabolic phenotype. Using a series of cytoplasmic hybrids, we establish that the complex I defect in UT946 stems from a nuclear-encoded loss-of-function mutation in the complex I subunit NDUFS1. To our surprise, the mutation in NDUFS1 was inherited as a recessive germline allele that underwent LOH in the tumor to expose functional loss of complex I. A reanalysis of 91 OCT tumor genomes revealed that LOH-driven exposure of recessive germline mutations in complex I subunits was a recurrent mechanism underlying complex I inactivation in OCT. These findings unveil a previously unidentified germline-driven mechanism of complex I loss and metabolic reprogramming in cancer and provide further evidence of the selective pressure for complex I impairment in OCT.
2. Impact of Telemedicine-Enhanced Integrated Management of Gestational Diabetes on Pregnancy Outcomes and Glycemic Control: Real-World Study Using TangMama App.
In a prospective real-world cohort of 4,621 women with GDM, adding a telemedicine app to standard care reduced gestational weight gain, cesarean section, hypertensive disorders, and multiple neonatal complications, while modestly improving third‑trimester HbA1c. Mediation analyses implicated gestational weight gain and fasting glucose; benefits scaled with engagement intensity.
Impact: Demonstrates clinically meaningful, multi-domain improvements in maternal and neonatal outcomes using scalable telemedicine, with dose–response and mediation insights informing implementation.
Clinical Implications: Supports integrating telemedicine into routine GDM pathways, prioritizing patient engagement to maximize benefits and targeting gestational weight gain and fasting glucose as intervention levers.
Key Findings
- Among 4,621 GDM patients, telemedicine-enhanced care reduced excessive gestational weight gain (aOR 0.61), cesarean section (aOR 0.80), and hypertensive disorders (aOR 0.76).
- Neonatal risks declined, including preterm birth (aOR 0.47), LGA (aOR 0.81), nursery admission (aOR 0.80), hypoglycemia (aOR 0.64), and hyperbilirubinemia (aOR 0.69).
- Third-trimester HbA1c improved (Δ −0.05%), and mediation analyses identified gestational weight gain and fasting glucose as significant mediators.
- Higher app engagement showed a dose–response association with improved glycemia and outcomes.
Methodological Strengths
- Prospective real-world cohort with large sample size and IPTW propensity adjustment
- Mediation and dose–response analyses elucidating mechanisms and engagement effects
Limitations
- Nonrandomized design with potential residual confounding and single-center setting
- HbA1c reduction was modest; generalizability beyond the study population requires confirmation
Future Directions: Conduct multicenter randomized trials to validate effectiveness, test engagement-optimization strategies, and evaluate cost-effectiveness and health equity impacts.
BACKGROUND: Gestational diabetes mellitus (GDM) is associated with substantial risks of adverse maternal and neonatal outcomes. Contemporary management approaches for GDM exhibit insufficient implementation, resulting in suboptimal glycemic control and preventable perinatal complications. The rapid evolution of mobile health technologies offers potential to enhance GDM care, yet evidence from large real-world studies remains limited. OBJECTIVE: This study aimed to evaluate the impact of a telemedicine-enhanced integrated management system on pregnancy outcomes and glycemic control in women with GDM and to explore the dose-response relationship between telemedicine engagement intensity and clinical outcomes. METHODS: In this real-world, prospective cohort study conducted at a provincial-level medical center in China, women with GDM were categorized into a standard care group and a telemedicine-enhanced group receiving the TangMama smartphone app in addition to standard care. We compared pregnancy outcomes and glycemic parameters between the 2 groups in an inverse probability of treatment weighting population based on propensity scores. Mediation analyses and dose-response analyses were additionally conducted to explore potential mechanisms and engagement effects. RESULTS: A total of 4621 women with GDM were included, with 1711 in the telemedicine-enhanced group and 2910 in the standard care group. Upon inverse probability of treatment weighting analysis, the telemedicine-enhanced group demonstrated significantly lower gestational weight gain (adjusted mean difference -1.49 kg, 95% CI -1.81 to -1.17), reduced rates of excessive gestational weight gain (adjusted odds ratio [aOR] 0.61, 95% CI 0.54-0.69), cesarean section (aOR 0.80, 95% CI 0.71-0.91), hypertensive disorders in pregnancy (aOR 0.76, 95% CI 0.64-0.90), and pre-eclampsia (aOR 0.64, 95% CI 0.49-0.83). Glycemic control in the third trimester was significantly improved, with lower glycated hemoglobin A1c (HbA1c) levels (adjusted mean difference -0.05%, 95% CI -0.08 to -0.03) and higher HbA1c on-target rates. For neonatal outcomes, telemedicine-enhanced management was associated with lower rates of preterm birth (aOR 0.47, 95% CI 0.38-0.59), large-for-gestational age (aOR 0.81, 95% CI 0.69-0.96), neonatal unit admission (aOR 0.80, 95% CI 0.71-0.91), neonatal hypoglycemia (aOR 0.64, 95% CI 0.45-0.93), and neonatal hyperbilirubinemia (aOR 0.69, 95% CI 0.58-0.82). Mediation analyses identified gestational weight gain and third-trimester fasting plasma glucose as significant mediators. Higher telemedicine engagement was associated with improved glycemic control and reduced adverse outcomes in a dose-response manner. CONCLUSIONS: Telemedicine-enhanced integrated management is associated with improved maternal glycemic control and substantial reductions of adverse pregnancy outcomes among women with GDM. The observed dose-response relationship between engagement intensity and outcomes underscores the importance of promoting active patient participation. These findings support the broader integration of telemedicine into routine GDM care pathways to optimize maternal and neonatal health.
3. Conjoint association of gestational diabetes mellitus and hypertensive disorders of pregnancy with long-term risk of mortality: a population-based cohort study.
In 220,953 parous women from the UK Biobank followed for a median 12.9 years, GDM was associated with increased all-cause, premature, and CVD mortality. HDPs were linked to higher CVD mortality. Co-occurrence of GDM and HDPs conferred nearly fourfold higher all-cause and over fourfold higher premature mortality versus neither condition.
Impact: Quantifies long-term mortality risks associated with GDM and HDPs and highlights the synergistic risk when both occur, informing postpartum risk stratification and prevention.
Clinical Implications: Advocates integrated postpartum cardiometabolic surveillance and preventive care for women with GDM, especially those with concurrent HDPs, including aggressive CVD risk factor management.
Key Findings
- GDM was associated with higher all-cause (HR 1.57), premature (HR 1.60), and CVD mortality (HR 2.60).
- HDPs were associated with increased CVD mortality (HR 2.07), but not with all-cause or premature mortality.
- Co-occurrence of GDM and HDPs yielded HR 3.93 for all-cause and HR 4.31 for premature mortality versus neither condition.
Methodological Strengths
- Large population-based cohort with long follow-up and Cox modeling for multiple mortality endpoints
- Joint exposure analysis enabling assessment of combined effects of GDM and HDPs
Limitations
- Potential misclassification of pregnancy complications and residual confounding in observational design
- UK Biobank volunteer bias may limit generalizability to broader populations
Future Directions: Validate in diverse cohorts, evaluate targeted postpartum interventions, and integrate risk into care pathways and cardiovascular prevention guidelines.
BACKGROUND: Gestational diabetes mellitus (GDM) and hypertensive disorders of pregnancy (HDPs) are common maternal complications. We sought to evaluate the independent and joint association of GDM and HDPs with all-cause, premature, and cause-specific mortality. METHODS: We used data from the UK Biobank, which included 220 953 women who reported at least one live birth. Individual and joint associations of GDM and HDPs with all-cause, premature, and cause-specific mortality were estimated using Cox regression models. RESULTS: During a follow-up of 12.9 years, women who experienced GDM had a higher risk of all-cause (hazard ratio (HR) = 1.57; 95% confidence interval (CI) = 1.26-1.96), premature (HR = 1.60; 95% CI = 1.24-2.06) and cardiovascular disease (CVD) mortality (HR = 2.60; 95% CI = 1.70-3.96). Women with a history of HDPs had an increased risk for CVD mortality (HR = 2.07; 95% CI = 1.51-2.83), but the association with all-cause death and premature death was not significant. Individuals who encountered both GDM and HDPs had a 3.9-fold higher relative risk of all-cause mortality (HR = 3.93; 95% CI = 1.88-8.24]) and a 4.3-fold higher risk of premature mortality (HR = 4.31; 95% CI = 1.94-9.57), compared to those without GDM or HDPs. CONCLUSIONS: Women with GDM have a higher risk of all-cause, premature mortality and both risks were higher than the impacts of a history of HDPs based on a large-scale population. The co-occurrence of GDM and HDPs will deteriorate the aforementioned situation compared to a single cardiometabolic pregnancy complication.